Objective-To evaluate the long term health consequences of past occupational exposure to 2,3,7,8 tetrachlorodibenzo-pdioxin (TCDD). Methods Polychlorinated dioxins and furans have been identified as unwanted byproducts of numerous chemical and thermal processes.' The toxic potency of these planar halogenated compounds is well documented and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), the most toxic member of the class, has been shown to cause a wide range of effects including hyperplastic changes in epithelial tissues of the skin, liver, gastric mucosa, bile duct, and urinary bladder.2 It is an animal carcinogen and promotes skin, lung, and liver tumours under appropriate experimental conditions.34 The mechanisms through which TCDD acts to alter tumour incidence are unknown, but are unlikely to include direct genetic effects. Three recent mortality studies with exposure assessments supported by TCDD measurements in blood, have been interpreted as showing an increased risk of cancer in humans after dioxin exposure.25 The present investigation updates the mortality experience of one of the three cited studies,7 reports cancer incidence for the first time, and examines cancer outcomes in relation to dose of TCDD with more extensive biomonitoring than was previously available.
Increased cancer risk ratios were found with higher doses of TCDD and longer interval since first exposure for all sites combined and digestive and respiratory cancers in particular. Within the high dose group (> 1 uglkg body weight), total cancer mortality was increased > 20 years after first exposure (13 Polychlorinated dioxins and furans have been identified as unwanted byproducts of numerous chemical and thermal processes.' The toxic potency of these planar halogenated compounds is well documented and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), the most toxic member of the class, has been shown to cause a wide range of effects including hyperplastic changes in epithelial tissues of the skin, liver, gastric mucosa, bile duct, and urinary bladder.2 It is an animal carcinogen and promotes skin, lung, and liver tumours under appropriate experimental conditions.34 The mechanisms through which TCDD acts to alter tumour incidence are unknown, but are unlikely to include direct genetic effects. Three recent mortality studies with exposure assessments supported by TCDD measurements in blood, have been interpreted as showing an increased risk of cancer in humans after dioxin exposure.25 The present investigation updates the mortality experience of one of the three cited studies,7 reports cancer incidence for the first time, and examines cancer outcomes in relation to dose of TCDD with more extensive biomonitoring than was previously available.
Materials and methods

STUDY BACKGROUND
On 17 November 1953, an uncontrolled decomposition reaction occurred in a trichlorophenol (TCP) production unit owned by BASF AG and located in Ludwigshafen, Germany. Byproducts that escaped from the damaged autoclave contaminated surfaces throughout the immediate work area of the enclosed production building. Within days, workmen who were engaged in clean up efforts developed severe acne as well as other signs and symptoms and some were taken into hospital. The agent most likely to have caused these responses was not identified until 1957 when TCDD was chemically shown to be a byproduct p of TCP production and was shown to be a potent acnegen.9 1l
Further confirmation that TCDD had been present was provided by biomonitoring data collected more than 30 years after the incident.7' 1 These data showed increases of TCDD concentrations in blood lipid that related to both the extent of involvement in clean up activities and an employee's chloracne status. A non-linear regression model relating TCDD concentrations in blood lipid to duration of exposure under various working trations of other dioxin congeners with the possible exception of the 1,2,3,7,8-pentachlorinated congener were not increased and did not correlate with exposure or chloracne status. Most likely, residues from the damaged reactor were the primary, if not the sole, source of TCDD contamination in the unit because of its brief history of operation before the accident (several months) and the decision not to restart TCP operations thereafter. Employees were potentially exposed to residues contaminated with TCDD during the clean up and repair activities that lasted for about 4-5 months, during incidental maintenance work in the building after completion of the restoration work, and finally during demolition of the reactor portion of the building in 1968-9.
Health surveillance of exposed employees has been conducted on a recurring basis since 1953. Descriptive accounts of the signs and symptoms experienced after exposure have been reported as well as laboratory studies correlating biomonitoring data with clinical chemistries, immunological variables, and cytogenetic outcomes; mortality follow up studies; and most recently a long term morbidity study based on medical insurance data have been reported.7 [11] [12] [13] [14] These investigations identified 115 cases of chloracne (56 classified as severe) in a cohort of 254 people." Most cases were diagnosed during the early clean up period and no severe cases were found after 1959. Up to 1988, a twofold increase in cancer deaths was found > 20 years after first exposure among people with chloracne or erythema.7 Clinical investigations and a sickness absenteeism study of this same population have identified the thyroid, immune system, and digestive organs as possible sites of injury induced by TCDD. Findings have included dose-related increases in thyroid disease, infectious and parasitic disease, appendicitis, and chronic liver disease. STUDY there has been one death due to unknown causes and one case of bladder cancer diagnosed when cohort eligibility was decided. A subcohort of 69 people (68 men, the Cl subcohort) is of particular interest because each member had been diagnosed with chloracne and was included on a list of exposed employees on 5 May 1954.
In the earlier mortality study, vital status to 1988 had been ascertained for all cohort members through company records and contacts with local residents' registration offices.7 These same sources were used to trace vital status until 1993. For dead men, copies of death certificates were sought with the assistance of the Berufsgenossenschaft der chemischen Industrie and coded for underlying cause by the 9th revision of the international classification of diseases (ICD-9). Vital status up to and including 1992 was successfully determined for all cohort members and death certificates were obtained for all but one of the dead workers.
The sources of incident cancer cases were the occupational medical records of employees, death certificate records, doctor's letters, necropsy reports for those who died, and survey results obtained through questionnaires sent to all surviving cohort members. The questionnaire included a consent form to allow diagnostic follow up with the person's personal physician. For non-respondents, a follow up telephone call was made and a second questionnaire sent. The quality and completeness of the diagnostic information could not be evaluated against tumour [5] [6] [7] [8] years found for these people is lower than the 5-8 to 7-1 years reported for other populations exposed to TCDD'5 and considerably lower than recent estimates of 10 to 14 years based on data for veterans of Operation Ranch Hand. '6 Evidence that TCDD half life increases with higher percentages of body fat has been reported in mammals,'7 and most recently in humans. '6 This tendency was also found within the present population and so individual rates of decay of TCDD were regressed on percentages of body fat to accommodate variable lengths of decay in our procedure of extrapolating back. Percentages of body fat were estimated from body mass index (BMI) as in Wolfe et al. '6 Our regression model yielded half life estimates of 5-1 and 8-9 years for people with 20% and 30% body fat, respectively. In the previous exposure assessment for this cohort, a fixed half life of seven years had been assumed. "
Current dioxin body burdens were estimated by multiplying the TCDD concentrations in blood lipid by the estimated total lipid weight for each person assuming a homogeneous distribution of TCDD throughout all fat tissues. This assumption is supported by the work of Patterson et all5 and by limited biopsy and necropsy data for several members of the present cohort.'8 A non-linear regression model was then fitted to find the contribution of duration of exposure under the various work conditions to the TCDD dose, extrapolated back to the time of exposure." The final step was to calculate a TCDD dose estimate from the model for each cohort member and to divide that quantity by the person's weight at the time of first exposure. A correlation of 0 97 between this measure and the TCDD concentration previously reported by backward extrapolation indicates that either measure would produce similar results in dose-response analyses. Our TCDD dose estimates could be low for employees with the highest exposure intensities if clearance is biphasic at very high levels of intake.
As well as the two TCDD exposure measures, data were collected on age, smoking history, BMI at the time of first exposure, and history of occupational exposure to aromatic amines (namely, B-naphthylamine) and asbestos. There were 23 people who had reported working with aromatic amines and 16 with asbestos. Of the 23 people with past potential exposure to f3-naphthylamine, 20 had been assigned to a nearby aromatic amine production unit. Potential past exposure to Internal dose response analyses were based on the Cox's proportional hazard model with a SAS program (Proc PHREG, SAS Release 6 10). This approach enabled us to include cigarette smoking, BMI, and other potentially confounding exposures in the regression analyses. Occupational exposures to asbestos and aromatic amines were treated as dichotomous variables. The BMI values below 26 kg/M2 were assigned a score value of 26. Actual BMI values were used for the remaining people. This was done because increased mortality risks are associated with BMI measurements above 26 kg/m2.2' Smoking data were scored as: 1 (never smoked cigarettes or former cigarette smoker) and 2 (current cigarette smoker). Among the exposure variables only TCDD dose was treated as a time dependent covariate. A stratified analysis approach based on date of first exposure was followed to minimise potential confounding between calendar time and exposure. The three strata were: first exposure within one year of the accident (168 men), first exposure more than one year after the accident and before 1960 (18 men), and first exposure after 1959 (57 men). A stepwise procedure was used in constructing models and results were summarised in terms of conditional risk ratios (CRs) and 95% CIs.
Results Table 1 shows the distribution of cohort members by estimated TCDD dose, chloracne status, cigarette smoking category, and BMI at the time of first exposure. The highest estimated TCDD dose for any person was yug/kg body weight. Among the 243 men, there Mortality experience within the C1 subcohort parallels that found for the total cohort with 34 observed v 35-8 expected deaths. Cancer mortality was only marginally increased (12 observed v 8-8 expected deaths); however, 10 of the cancer deaths (5-9 expected) occurred among people whose TCDD dose estimates exceeded 1 jg/kg body weight. The six digestive cancers (3-2 expected) included three deaths from stomach cancer (1-2 expected). Individual dose estimates for the five respiratory cancer deaths were all above 1 jug/kg body weight. As cause of death (n = Table 4 shows the Cox's regression results. Cigarette smoking was significantly related to overall mortality, to total cancer mortality and incidence, and to respiratory cancer mortality and incidence. Cigarette smoking was also marginally related to deaths from circulatory disease (CR 1-46, 95% CI 0 95-2-25). The BMI was significantly related to total mortality, deaths due to circulatory disease, and other incident cases of cancer. Exposure to aromatic amines (f3-naphthylamine) was marginally related to other incident cases of cancer (CR 2-50, 95% CI 0-87-7-16) but not to other outcomes. Past asbestos exposure was not a significant predictor of any health outcome. There had been one death due to mesothelioma in an employee with past asbestos exposure whose TCDD dose was less than 01 yug/kg body weight.
The TCDD dose was not related to either deaths due to all causes or deaths due to circulatory disease. There was an increase in overall cancer mortality with higher TCDD dose and significantly increased risk ratios for digestive cancer, but not for respiratory cancer. The conditional risk was expressed as the risk per unit (1 Mg/kg body weight) increase in TCDD dose. Review of the digestive cancer cases showed that three cases had occurred among the four most exposed employees in the entire cohort. The primary tumour sites were liver (TCDD dose estimate, 8-3 jg/kg body weight), stomach (TCDD dose estimate 6-8 ag/kg body weight), and pancreas (TCDD dose estimate 6-1 pg/kg body weight). The highest TCDD dose estimate for any respiratory cancer was 2-4 jg/kg body weight. Analyses with chloracne status as an exposure surrogate instead of TCDD dose were unremarkable.
DOSE OF TCDD AND CIGARETTE SMOKING
Additional SMR analyses were performed to examine the joint effects of TCDD and cigarette smoking on cancer outcomes. The pattern of observed and expected cancer deaths suggests a positive dose-response gradient for TCDD among active cigarette smokers but not among non-smokers (table 5) . Twelve of the cancer deaths (3 5 expected deaths with general population death rates) occurred Table 5 Observed deaths and standardised mortality ratios (SMRs) for deaths due to total malignant neoplasms by TCDD dose and cigarette smoking, The case for respiratory cancer rests primarily on the external comparisons, which showed more deaths from respiratory cancer than expected in the high TCDD dose group. Among the 11 cases of lung cancer only one reported having never smoked cigarettes. The reported histology of this case was large cell carcinoma and the estimated TCDD dose was 1-4 jug/kg body weight. All other cases had smoked cigarettes although only three reported heavy cigarette smoking. Review of histology data for nine cases suggests that small cell carcinoma (five cases) was somewhat more prevalent than in other case series." Although we previously found an increased rate of absenteeism due to upper respiratory tract infections, episodes of pneumonia and chronic obstructive lung disease were not notably increased and deaths due to respiratory disease were significantly below expectation in the total cohort. Given that most lung cancer cases occurred among known cigarette smokers, it would seem that any effect related to TCDD is indirect; however, the lack of a TCDD dose-response trend among non-smokers could also be a consequence of small sample size.
For digestive cancer, there was about a 50% increase in deaths among people with a TCDD dose above 0 1 jg/kg body weight based on nine cases. There was no dominant cancer site; however, there were three deaths from stomach cancer and the death from hepatocellular carcinoma occurred in the person with the highest estimated TCDD dose. Surveillance of this population is ongoing and thus continues to provide new facts on both the exposure and health status of employees. Recently, blood specimens for TCDD analysis were provided by three more cohort members. For one of the men, the TCDD concentration of 237 pg/g blood lipid in 1995 was much higher than predicted by our regression model. In a follow up interview, this person described a previously unknown incident in which he had been exposed to a soot cloud released during work on the damaged autoclave two days after the accident. He subse-quently developed severe chloracne and lost time from work due to illness, both of which were documented in the medical records. In 1960, he was treated for appendicitis. Currently, he shows no active acnegenic lesions or evidence of scaring and he has never smoked cigarettes or been diagnosed with cancer.
Our overall findings are consistent with an increase in cancer risks induced by TCDD in people with past TCDD exposures sufficient to produce other signs of toxicity. A positive dose-response gradient was evident among cigarette smokers, but not among non-smokers. Unfortunately, with such a small cohort, the risk estimates are not very stable and we are unable to assess whether TCDD might be exerting an influence independent of other cancer risk factors.
The strengths of this study include the exposure assessment, the nearly 40 year follow up period, an extensive clinical data base supporting our health outcome assessment, and the availability of cigarette smoking histories for most people. Limitations stem from the small size of the study population, the possibility of unknown confounding exposures, and the potential for biases in reporting illness and detecting diagnoses that is linked to the considerable medical attention received by cohort members over the years. 
